Justine Konigsberg
Head of Investor Relations
Replay available
Kymera Therapeutics, Inc. (KYMR) Q1 2025 Earnings Call
Kymera Therapeutics, Inc. (NASDAQ: KYMR) Q1 2025 earnings conference call, held 2025-05-09. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Nello Manolfi
Founder, President, and CEO
Jared Golub
Chief Medical Officer
Veronica Campbell
Senior Director of Immunology and Project Team Leader
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Kymera Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.476 Good morning and welcome to Chimera's Immunology Innovation Day, our virtual event to 00:00:04.476 -- 00:00:08.101 introduce our next immunology program, IREF5. 00:00:08.101 -- 00:00:11.945 I'm Justine Konigsberg, Chimera's Head of Investor Relations. 00:00:11.945 -- 00:00:16.811 Please note that we are hosting today's event in lieu of our regularly scheduled quarterly 00:00:16.811 -- 00:00:21.897 update call. However, we have reported our results and filed our 10Q this morning. 00:00:21.897 -- 00:00:26.543 For additional details on our Q1 results, please reference our press release issued this 00:00:26.543 -- 00:00:30.541 morning, which is available in the IR section of our website. 00:00:30.541 -- 00:00:34.627 During today's presentation, you'll hear from our team about our strategy, our pipeline 00:00:34.627 -- 00:00:38.734 advancements, and our next high-value immunology program. 00:00:38.734 -- 00:00:43.741 Joining me this morning are Nello Manolfi, our founder, president, and CEO, Jared Golub, 00:00:43.741 -- 00:00:48.789 our chief medical officer, and Veronica Campbell, our senior director of immunology and 00:00:48.789 -- 00:00:53.954 project team leader of our newly introduced program, IRAF5. 00:00:54.352 -- 00:00:58.862 Here's a snapshot of today's agenda. Nello will begin with an overview of our strategy 00:00:58.862 -- 00:01:02.008 and the opportunity with small molecule degraders. 00:01:02.008 -- 00:01:06.117 Then Jared will provide a high level overview of our STAT6 program. 00:01:06.117 -- 00:01:10.065 And we'll conclude with our prepared remarks with a discussion of our newly introduced 00:01:10.065 -- 00:01:13.892 IRA5 program before we open the call to questions. 00:01:13.892 -- 00:01:17.798 If you'd like to ask a...